JP2013542246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542246A5 JP2013542246A5 JP2013538280A JP2013538280A JP2013542246A5 JP 2013542246 A5 JP2013542246 A5 JP 2013542246A5 JP 2013538280 A JP2013538280 A JP 2013538280A JP 2013538280 A JP2013538280 A JP 2013538280A JP 2013542246 A5 JP2013542246 A5 JP 2013542246A5
- Authority
- JP
- Japan
- Prior art keywords
- apomorphine
- kit
- levodopa
- parkinson
- combined according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004046 apomorphine Drugs 0.000 claims 18
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 18
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 7
- 208000018737 Parkinson disease Diseases 0.000 claims 7
- 229960004502 levodopa Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 4
- 229940052760 dopamine agonists Drugs 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 208000010340 Sleep Deprivation Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1019291.2A GB201019291D0 (en) | 2010-11-15 | 2010-11-15 | Compositions and uses |
| GB1019291.2 | 2010-11-15 | ||
| GB1101924.7 | 2011-02-04 | ||
| GBGB1101924.7A GB201101924D0 (en) | 2011-02-04 | 2011-02-04 | Compositions and uses |
| GBGB1107454.9A GB201107454D0 (en) | 2011-05-05 | 2011-05-05 | Compositions and uses |
| GB1107454.9 | 2011-05-05 | ||
| PCT/GB2011/052222 WO2012066319A1 (en) | 2010-11-15 | 2011-11-15 | Apomorphine by pulmonary inhalation, oprionally in combination with l-dopa or a dopamine agonist for use in the treatment of parkinson |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013542246A JP2013542246A (ja) | 2013-11-21 |
| JP2013542246A5 true JP2013542246A5 (enExample) | 2015-01-08 |
Family
ID=45099135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538280A Pending JP2013542246A (ja) | 2010-11-15 | 2011-11-15 | パーキンソン病の処置において用いるための、任意選択によってｌ−ドーパまたはドパミンアゴニストと組み合わされる、肺吸入によるアポモルヒネ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130287854A1 (enExample) |
| EP (1) | EP2640374A1 (enExample) |
| JP (1) | JP2013542246A (enExample) |
| AR (1) | AR084498A1 (enExample) |
| TW (1) | TW201304822A (enExample) |
| WO (1) | WO2012066319A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015534988A (ja) * | 2012-10-22 | 2015-12-07 | サイヴィタス セラピューティックス，インコーポレイテッド | レボドパの血漿濃度の患者間のばらつきの低減 |
| KR20210075224A (ko) | 2012-10-22 | 2021-06-22 | 키비타스 테라퓨틱스, 인코포레이티드. | 파킨슨병의 빠른 경감을 위한 레보도파 제형 |
| WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| US8545878B1 (en) * | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
| WO2014205030A1 (en) * | 2013-06-19 | 2014-12-24 | Map Pharmaceuticals, Inc. | Pulmonary administration of rotigotine |
| US20140377365A1 (en) * | 2013-06-19 | 2014-12-25 | Map Pharmaceuticals, Inc. | Sustained-release formulation of rotigotine |
| TWI589308B (zh) | 2014-03-25 | 2017-07-01 | 林信湧 | 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法 |
| IL309959A (en) * | 2014-04-21 | 2024-03-01 | Civitas Therapeutics Inc | Rapid relief of motor fluctuating episodes in Parkinson's disease |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| MX2018016046A (es) | 2016-06-27 | 2019-05-02 | Achillion Pharmaceuticals Inc | Quinazolina y compuestos indol para tratar trastornos medicos. |
| FI3985002T3 (fi) | 2017-03-01 | 2025-07-30 | Achillion Pharmaceuticals Inc | Aryyli-, heteroaryyli- ja heterosyklisiä lääkeyhdisteitä sairauksien hoitoon |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| US11612613B2 (en) | 2017-08-08 | 2023-03-28 | Robert Petcavich | Formulations for the delivery of autophagy stimulating Trehalose |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| KR20210034047A (ko) * | 2018-07-19 | 2021-03-29 | 임펠 뉴로파마 인코포레이티드 | 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달 |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| EP3840754A4 (en) * | 2018-08-23 | 2022-09-14 | Sunovion Pharmaceuticals Inc. | ACID ADDITIONAL SALTS OF APOMORPHINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE THEREOF |
| CN113365617B (zh) | 2018-10-16 | 2025-12-23 | 乔治亚州立大学研究基金会股份有限公司 | 用于医学疾病治疗的一氧化碳前药 |
| CA3252762A1 (en) | 2019-04-12 | 2025-07-08 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| CN119837855A (zh) | 2019-12-19 | 2025-04-18 | 乔治亚州大学研究基金会 | 用于治疗细菌感染和增强抗生素的化合物 |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| JP2023538859A (ja) * | 2020-08-31 | 2023-09-12 | パーデュー、ファーマ、リミテッド、パートナーシップ | レボドパ送達のための組成物及び方法 |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022445A2 (en) | 1993-03-26 | 1994-10-13 | Merkus Franciscus W H M | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US6193954B1 (en) | 1997-03-21 | 2001-02-27 | Abbott Laboratories | Formulations for pulmonary delivery of dopamine agonists |
| US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
| GB2353222B (en) | 1999-06-23 | 2001-09-19 | Cambridge Consultants | Inhalers |
| CN100551358C (zh) | 2000-06-27 | 2009-10-21 | 维克多瑞有限公司 | 用于药物组合物的颗粒的制备方法 |
| GB2364919A (en) | 2000-07-21 | 2002-02-13 | Cambridge Consultants | Inhalers |
| US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| AU2211502A (en) | 2000-11-30 | 2002-06-11 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
| GB2375308A (en) | 2001-05-10 | 2002-11-13 | Cambridge Consultants | Inhalers |
| CA2444729A1 (en) | 2001-05-10 | 2002-11-14 | Vectura Delivery Devices Limited | Inhalers |
| EP1613323A1 (en) * | 2003-04-14 | 2006-01-11 | Vectura Limited | Pharmaceutical compositions comprising apomorhine for pulmonary inhalation |
| WO2005025535A2 (en) | 2003-09-15 | 2005-03-24 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| BRPI0914902B8 (pt) * | 2008-06-06 | 2022-04-12 | Pharma Two B Ltd | Composição farmacêutica para uso no tratamento de mal de parkinson |
| GB0901520D0 (en) | 2009-01-30 | 2009-03-11 | Vectura Delivery Devices Ltd | Inhaler |
-
2011
- 2011-11-14 TW TW100141420A patent/TW201304822A/zh unknown
- 2011-11-15 EP EP11791618.9A patent/EP2640374A1/en not_active Withdrawn
- 2011-11-15 WO PCT/GB2011/052222 patent/WO2012066319A1/en not_active Ceased
- 2011-11-15 US US13/885,531 patent/US20130287854A1/en not_active Abandoned
- 2011-11-15 JP JP2013538280A patent/JP2013542246A/ja active Pending
- 2011-11-16 AR ARP110104270A patent/AR084498A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542246A5 (enExample) | ||
| JP2022058688A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2011502997A5 (enExample) | ||
| JP2013516442A5 (enExample) | ||
| JP2013528600A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| NZ612686A (en) | Sublingual films | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| JP2010222367A5 (enExample) | ||
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| NZ623495A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| JP2015515475A5 (enExample) | ||
| JP2010522137A5 (enExample) | ||
| JP2013516493A5 (enExample) | ||
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| JP2013508289A5 (enExample) | ||
| JP2012502047A5 (enExample) | ||
| JP2015514739A5 (enExample) | ||
| JP2015537009A5 (enExample) | ||
| RU2014129508A (ru) | Новая комбинация | |
| JP2016530291A5 (enExample) | ||
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. |